Cargando…
Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes
It is now well-established that the therapy of type II diabetes mellitus has undergone a radical change in the past 15 years: countless innovative drugs, such as SGLT2I, able to guarantee an optimization of glycaemic control without causing hypoglycaemia, today represent real therapeutic cornerstone...
Autores principales: | Bragagni, Alessio, Piani, Federica, Borghi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503418/ https://www.ncbi.nlm.nih.gov/pubmed/34650352 http://dx.doi.org/10.1093/eurheartj/suab094 |
Ejemplares similares
-
Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials
por: Yin, Daogen, et al.
Publicado: (2021) -
Gliflozine – in Zukunft Kardioprotektiva?
por: Rauch-Kröhnert, Ursula, et al.
Publicado: (2021) -
The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
por: Borghi, Claudio, et al.
Publicado: (2020) -
Therapy of Type 2 diabetes: more gliflozines and less metformin?
por: Verdecchia, Paolo, et al.
Publicado: (2023) -
Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure
por: Pistelli, Lorenzo, et al.
Publicado: (2023)